Related Experiment Videos
[Thiazolidinediones: clinical data and perspectives]
1Service de Médecine Interne, Diabétologie et Maladies Métaboliques Hôpitaux Universitaires de Strasbourg, Cedex, France. Jean-Frederic.Blickle@chru-strasbourg.fr
Diabetes & Metabolism
|July 14, 2001
Summary
Thiazolidinediones (TZDs) like rosiglitazone and pioglitazone effectively lower blood glucose and HbA1c in type 2 diabetes. They show varied effects on lipid profiles and are generally well-tolerated, excluding troglitazone
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Thiazolidinediones (TZDs) are a class of drugs used to manage type 2 diabetes.
- Clinical studies have evaluated troglitazone, rosiglitazone, and pioglitazone for their efficacy and safety.
Purpose of the Study:
- To synthesize and compare the clinical findings of three major thiazolidinediones.
- To evaluate their effects on glycemic control, lipid metabolism, and safety profiles.
Main Methods:
- Review of main clinical studies for troglitazone, rosiglitazone, and pioglitazone.
- Comparison of their effects on fasting plasma glucose, HbA1c, and lipid parameters.
- Assessment of adverse effects and therapeutic potential.
Main Results:
- All TZDs show similar efficacy in reducing fasting plasma glucose and HbA1c at optimal doses.
- Lipid metabolism effects vary: rosiglitazone and pioglitazone increase HDL-cholesterol; troglitazone and pioglitazone decrease triglycerides.
- Troglitazone caused hepatotoxicity, leading to its withdrawal; other TZDs are generally well-tolerated but can cause edema, anemia, and weight gain.
Conclusions:
- TZDs are effective in managing type 2 diabetes, with differentiated effects on lipid profiles.
- Potential beta-cell protective effects warrant further investigation.
- Current European licensing restricts use, but broader indications may follow long-term study results.